 Generic drugmakers like Mylan benefited in the first quarter from customers stocking up on over-the-counter medicines ahead of the lockdowns imposed to curb the spread of the virus. The stockpiling, however, meant that patients bought fewer drugs in the second quarter, weighing on sales outside North America and the company now expects 2020 revenue of between 11.5 billion and 12.0 billion, versus up to 12.50 billion previously. Mylan, which sells a cheaper version of Gilead Sciences Incs COVID-19 drug remdesivir, took a roughly 5 hit to sales of products in Europe and the rest of the world as non-COVID-19 related hospital visits fell during the pandemic. 